ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Long-term Use of Growth Hormone Does Not Increase Cancer Risks
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 111942" data-attributes="member: 3"><p><span style="font-size: 10px"><span style="font-family: 'Arial'"><a href="https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13502" target="_blank">https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13502</a></span></span></p><p><span style="font-size: 10px"><span style="font-family: 'Arial'"></span></span></p><p><span style="font-size: 10px"><span style="font-family: 'Arial'"></span></span></p><p><span style="font-size: 10px"></span><span style="font-size: 10px"><strong>Long&#8208;term safety of growth hormone—A combined registry analysis</strong></span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px"><strong>Objectives</strong></span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px">Preliminary data from the French cohort of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) study raised concerns regarding the safety of recombinant human GH, suggesting that GH may increase mortality and incidence of stroke in patients treated during childhood for GH deficiency or short stature. We evaluated published safety data, focusing on mortality, neoplasms, cerebrovascular events and diabetes across a number of large&#8208;scale pharmaceutical company GH registries.</span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px"><strong>Design</strong></span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px">A literature review was conducted using PubMed, EMBASE and Google Scholar to identify all relevant safety data from manufacturers' GH registries published between 1988 and April 2016. Results were hand&#8208;sorted to exclude nonrelevant publications; bibliographic references from retrieved articles were evaluated for any additional references.</span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px"><strong>Results</strong></span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px">The published data do not support an increased risk of mortality in children or adults treated with GH. There was no evidence of an increased risk of stroke, new malignancy,</span><span style="font-size: 10px">leukaemia</span><span style="font-size: 10px">, nonleukaemic extracranial </span><span style="font-size: 10px">tumours</span><span style="font-size: 10px"> or recurrence of intracranial malignancy in patients without risk factors. The risk of a second neoplasm is increased, particularly if patients have received radiation therapy for a central nervous system </span><span style="font-size: 10px">tumour</span><span style="font-size: 10px">. There may be an increased risk of type 2 diabetes in GH&#8208;treated patients, but this appears to be confined to those with pre&#8208;existing risk factors.</span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px"><strong>Conclusions</strong></span></p><p><span style="font-size: 10px"></span></p><p><span style="font-size: 10px">Patients with risk factors for malignancy or type 2 diabetes should be treated with caution and monitored during follow&#8208;up, but current published data provide reassurance on the long&#8208;term safety profile of GH in patients receiving GH treatment.</span></p><p></p><p></p><p></p><p></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 111942, member: 3"] [SIZE=2][FONT=arial][URL]https://onlinelibrary.wiley.com/doi/full/10.1111/cen.13502[/URL] [/FONT] [/SIZE][FONT=-apple-system-font][SIZE=2][B]Long‐term safety of growth hormone—A combined registry analysis[/B] [B]Objectives[/B] Preliminary data from the French cohort of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) study raised concerns regarding the safety of recombinant human GH, suggesting that GH may increase mortality and incidence of stroke in patients treated during childhood for GH deficiency or short stature. We evaluated published safety data, focusing on mortality, neoplasms, cerebrovascular events and diabetes across a number of large‐scale pharmaceutical company GH registries. [B]Design[/B] A literature review was conducted using PubMed, EMBASE and Google Scholar to identify all relevant safety data from manufacturers' GH registries published between 1988 and April 2016. Results were hand‐sorted to exclude nonrelevant publications; bibliographic references from retrieved articles were evaluated for any additional references. [B]Results[/B] The published data do not support an increased risk of mortality in children or adults treated with GH. There was no evidence of an increased risk of stroke, new malignancy,[/SIZE][SIZE=2]leukaemia[/SIZE][SIZE=2], nonleukaemic extracranial [/SIZE][SIZE=2]tumours[/SIZE][SIZE=2] or recurrence of intracranial malignancy in patients without risk factors. The risk of a second neoplasm is increased, particularly if patients have received radiation therapy for a central nervous system [/SIZE][SIZE=2]tumour[/SIZE][SIZE=2]. There may be an increased risk of type 2 diabetes in GH‐treated patients, but this appears to be confined to those with pre‐existing risk factors. [B]Conclusions[/B] Patients with risk factors for malignancy or type 2 diabetes should be treated with caution and monitored during follow‐up, but current published data provide reassurance on the long‐term safety profile of GH in patients receiving GH treatment.[/SIZE] [/FONT] [FONT=-apple-system-font] [/FONT] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Peptide Forums (GHRH, Sermorelin, etc)
General Peptide Use & Information
Long-term Use of Growth Hormone Does Not Increase Cancer Risks
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top